Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Madhuri Wadehra
University of California Los Angeles, Department: Pathology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paganini Biosciences, LLC
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
Professor Wadehra is the inventor of intellectual property that will be used in her research. The intellectual property has been licensed by The Regents to Paganini Biosciences, LLC, a virtual company currently seeking a licensing partner. Professor Wadehra will take the overall lead in experimental design, implementation, data analysis, and strategic planning for EMP2 directed therapy. Professor Wadehra will also directly supervise technicians and postdoctoral fellows involved in the project.
Using EMP2 for Image Guided Drug Delivery for Breast Cancer
Despite significant advances in biology and medicine, the incidence and mortality due to breast cancer world- wide is still unacceptably high. Breast cancer remains the 5th most common cause of death in women. Recently, we have identified a protein epithelial membrane protein-2 (EMP2) that is upregulated in 68% of all breast cancer tumors and 73% of triple negative tumors tested. In the studies proposed here, we present a novel and exciting imaging guided therapeutic approach through the targeting of EMP2 in breast cancer.
Filed on April 23, 2014.
Tell us what you know about Madhuri Wadehra's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Madhuri Wadehra filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Madhuri Wadehra | University of California Los Angeles | Conflict of Interest | Paganini Biosciences, LLC | Value cannot be readily determined |
Other search results for: “Madhuri Wadehra”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Madhuri Wadehra | University of California Los Angeles | Financial Disclosure | Paganini Biopharma, Inc. - (Prime NIH/NCI) | |
| Madhuri Wadehra | University of California Los Angeles | Financial Disclosure | Paganini Biopharma, Inc. - (Prime NCI) | |
| Madhuri Wadehra | University of California Los Angeles | Financial Disclosure | Paganini Biopharma, Inc. - (Prime NCI) |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.